Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | CA1 | P00915 | 11/20 | 0.61 |
| ▸ | CA2 | P00918 | 11/20 | 0.61 |
| ▸ | CA12 | O43570 | 8/20 | 0.61 |
| ▸ | CA9 | Q16790 | 8/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | GBA1 | P04062 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | CA6 | P23280 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890706 | 0.95 | ALDH1A1 (0.61) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL11251792 | 0.91 | ALDH1A1 (0.56) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL6789998 | 0.86 | CA1 (0.57) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL6789995 | 0.86 | CA1 (0.57) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL9229800 | 0.85 | ALDH1A1 (0.67) | ALDH1A1CA1CA2GBA1GAA | |
| SCHEMBL7862567 | 0.83 | GBA1 (0.74) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL31234593 | 0.83 | CA1 (0.54) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL3704958 | 0.82 | CA12 (0.71) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL20946436 | 0.82 | ALDH1A1 (0.73) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL2934786 | 0.81 | ALDH1A1 (0.67) | ALDH1A1CA1CA2GBA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024243485-A1 | CDK2 INHIBITORS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-06-10 | — | — | US | disclosed |
| US-6638921-B1 | Pharmaceutically acceptable derivatives thereof Cx, R1 and R2 being as defined in the disclosure may be used to inhibit the activity of HIV integrase. | PHARMACOR INC. (CA) | 2003-10-28 | — | — | US | disclosed |
| EP-1353922-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | Cancer Research Technology Limited (GB) | 2003-10-22 | — | — | EP | disclosed |
| WO-2003082881-A2 | PYRIDOXAL-5-PHOSPHATE DERIVATIVES AS HIV INTEGRASE INHIBITORS | PROCYON BIOPHARMA INC. (CA) | 2003-10-09 | — | — | WO | disclosed |
| WO-2002059125-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
| EP-0644453-A1 | Organic nonlinear optical materials | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CCNA1, CDKL1, CCNK | ALDH1A1 2396/4885CA1 2976/4885CA2 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.